孤儿药市场报告（按药物类型、疾病类型、阶段、畅销药物、配销通路和地区划分）2025 年至 2033 年

2024IMARC Group全球孤儿药市场规模达到 2,373 亿美元。

孤儿药是指用于诊断、预防和治疗罕见疾病的药品。这些药物是为了满足特定的公共卫生要求而生产的，而且由于是为一小部分患者生产的，因此通常市场有限。它们对多种肿瘤、代谢、血液、免疫、传染病和神经疾病有效。淋巴瘤、白血病、囊性纤维化、神经胶质瘤、胰臟癌、卵巢癌、多发性骨髓瘤和肾细胞癌等疾病通常具有生命危险，且是慢性、进行性、退化性和致残性的，需要针对特定症状有效的特定治疗方案。

孤儿药市场趋势：

癌症和其他罕见遗传疾病的发生率不断上升是推动市场成长的关键因素之一。製药商正在开发创新的孤儿药，为患者提供个人化治疗。大众对孤儿药益处的认识不断提高，这也推动了市场的发展。新的药品製造商的出现和政府为抑制传染病传播而实施的优惠政策也促进了市场的成长。此外，各种产品创新，如生物孤儿药的开发，也扮演了其他成长促进因素的角色。这些药物可以治疗癌症等疾病，并逆转对干细胞造成的伤害，这极大地促进了它们的整体需求。其他因素，包括医疗保健基础设施的改善以及广泛的研究和开发（R&D）活动，预计将进一步推动市场发展。

本报告解答的关键问题

• 2024 年全球孤儿药市场规模？ 2025-2033年全球孤儿药市场的预期成长率是多少？
• 推动全球孤儿药市场发展的关键因素有哪些？
• COVID-19 对全球孤儿药市场有何影响？
• 根据药物类型，全球孤儿药市场是如何分布的？
• 根据疾病类型，全球孤儿药市场如何分布？
• 根据最畅销药物，全球孤儿药市场如何分布？
• 根据配销通路，全球孤儿药市场分布如何？
• 全球孤儿药市场的主要区域有哪些？
• 全球孤儿药市场的主要参与者/公司有哪些？

目录

第 1 章：前言

第 2 章：范围与方法

• 研究目标
• 利害关係人
• 资料来源
  • 主要来源
  • 次要来源
• 市场预测
  • 自下而上的方法
  • 自上而下的方法
• 预测方法

第 3 章：执行摘要

第 4 章：简介

• 概述
• 主要行业趋势

第 5 章：全球孤儿药市场

• 市场概况
• 市场表现
• COVID-19 的影响
• 市场预测

第 6 章：市场区隔：依药物类型

• 生物
  • 市场趋势
  • 市场预测
• 非生物
  • 市场趋势
  • 市场预测

第七章：市场区隔：依疾病类型

• 肿瘤学
  • 市场趋势
  • 市场预测
• 血液学
  • 市场趋势
  • 市场预测
• 神经病学
  • 市场趋势
  • 市场预测
• 心血管
  • 市场趋势
  • 市场预测
• 其他的
  • 市场趋势
  • 市场预测

第 8 章：市场区隔：依阶段

• 第一阶段
  • 市场趋势
  • 市场预测
• 第二阶段
  • 市场趋势
  • 市场预测
• 第三阶段
  • 市场趋势
  • 市场预测
• 第四阶段
  • 市场趋势
  • 市场预测

第 9 章：市场区隔：按畅销药物

• 来那度胺
  • 市场趋势
  • 市场预测
• 利妥昔单抗
  • 市场趋势
  • 市场预测
• 克帕松
  • 市场趋势
  • 市场预测
• 奥狄沃
  • 市场趋势
  • 市场预测
• 可瑞达 (Keytruda)
  • 市场趋势
  • 市场预测
• 依鲁替尼
  • 市场趋势
  • 市场预测
• 艾沃尼克斯
  • 市场趋势
  • 市场预测
• 森西帕尔
  • 市场趋势
  • 市场预测
• 索立利
  • 市场趋势
  • 市场预测
• 其他的
  • 市场趋势
  • 市场预测

第 10 章：市场区隔：按配销通路

• 医院药房
  • 市场趋势
  • 市场预测
• 零售药局
  • 市场趋势
  • 市场预测
• 线上商店
  • 市场趋势
  • 市场预测
• 其他的
  • 市场趋势
  • 市场预测

第 11 章：市场区隔：按地区

• 北美洲
  • 美国
  • 加拿大
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 韩国
  • 澳洲
  • 印尼
  • 其他的
• 欧洲
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙
  • 俄罗斯
  • 其他的
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 其他的
• 中东和非洲
  • 市场趋势
  • 市场区隔：依国家
  • 市场预测

第 12 章：SWOT 分析

• 概述
• 优势
• 弱点
• 机会
• 威胁

第 13 章：价值链分析

第 14 章：波特五力分析

• 概述
• 买家的议价能力
• 供应商的议价能力
• 竞争程度
• 新进入者的威胁
• 替代品的威胁

第 15 章：价格分析

第 16 章：竞争格局

• 市场结构
• 关键参与者
• 关键参与者简介
  • AbbVie Inc.
  • Alexion Pharmaceuticals Inc.
  • Amgen Inc.
  • Biogen Inc.
  • Bristol Myers Squibb Company
  • F. Hoffmann-La Roche AG (Roche Holding AG)
  • Jazz Pharmaceuticals Plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd

The global orphan drugs market size reached USD 237.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 582.5 Billion by 2033, exhibiting a growth rate (CAGR) of 9.97% during 2025-2033.

Orphan drugs refer to pharmaceutical products used for the diagnosis, prevention and treatment of rare medical disorders. These drugs are manufactured to meet a specific public health requirement and usually have a limited market as they are produced for a small group of patients. They are effective against numerous oncological, metabolic, hematologic, immunologic, infectious and neurological diseases. Medical ailments, such as lymphoma, leukemia, cystic fibrosis, glioma, pancreatic cancer, ovarian cancer, multiple myeloma and renal cell carcinoma, are often life-threatening, chronic, progressive, degenerative and disabling and require specific treatment alternatives that are effective for their particular symptoms.

Orphan Drugs Market Trends:

The increasing prevalence of cancer and other rare genetic disorders is one of the key factors driving the growth of the market. Pharmaceutical manufacturers are developing innovative orphan drugs to provide personalized therapy to patients. The market is also being driven by increasing awareness among the masses regarding the benefits of orphan drugs. The emergence of new pharmaceutical drug manufacturers and the implementation of favorable government policies to inhibit the spread of contagious diseases are also contributing to the market growth. Additionally, various product innovations, such as the development of biological orphan drugs, are acting as other growth-inducing factors. These drugs can treat diseases, such as cancer, and reverse the damage caused to the stem cells, which is facilitating their overall demand significantly. Other factors, including improvements in the healthcare infrastructure, along with extensive research and development (R&D) activities, are expected to drive the market further.

Key Market Segmentation:

Breakup by Drug Type:

• Biological
• Non-Biological

Breakup by Disease Type:

• Oncology
• Hematology
• Neurology
• Cardiovascular
• Others

Breakup by Phase:

• Phase I
• Phase II
• Phase III
• Phase IV

Breakup by Top Selling Drugs:

• Revlimid
• Rituxan
• Copaxone
• Opdivo
• Keytruda
• Imbruvica
• Avonex
• Sensipar
• Soliris
• Others

Breakup by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Stores
• Others

Breakup by Region:

• North America
• United States
• Canada
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being AbbVie Inc., Alexion Pharmaceuticals Inc., Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), Jazz Pharmaceuticals Plc, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

• 1.What was the size of the global orphan drugs market in 2024?
• 2.What is the expected growth rate of the global orphan drugs market during 2025-2033?
• 3.What are the key factors driving the global orphan drugs market?
• 4.What has been the impact of COVID-19 on the global orphan drugs market?
• 5.What is the breakup of the global orphan drugs market based on the drug type?
• 6.What is the breakup of the global orphan drugs market based on the disease type?
• 7.What is the breakup of the global orphan drugs market based on top selling drugs?
• 8.What is the breakup of the global orphan drugs market based on the distribution channel?
• 9.What are the key regions in the global orphan drugs market?
• 10.Who are the key players/companies in the global orphan drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Orphan Drugs Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Drug Type

• 6.1 Biological
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Non-Biological
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Disease Type

• 7.1 Oncology
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Hematology
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Neurology
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Cardiovascular
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by Phase

• 8.1 Phase I
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Phase II
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Phase III
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Phase IV
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by Top Selling Drugs

• 9.1 Revlimid
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Rituxan
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Copaxone
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Opdivo
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast
• 9.5 Keytruda
  • 9.5.1 Market Trends
  • 9.5.2 Market Forecast
• 9.6 Imbruvica
  • 9.6.1 Market Trends
  • 9.6.2 Market Forecast
• 9.7 Avonex
  • 9.7.1 Market Trends
  • 9.7.2 Market Forecast
• 9.8 Sensipar
  • 9.8.1 Market Trends
  • 9.8.2 Market Forecast
• 9.9 Soliris
  • 9.9.1 Market Trends
  • 9.9.2 Market Forecast
• 9.10 Others
  • 9.10.1 Market Trends
  • 9.10.2 Market Forecast

10 Market Breakup by Distribution Channel

• 10.1 Hospital Pharmacies
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Retail Pharmacies
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Online Stores
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast
• 10.4 Others
  • 10.4.1 Market Trends
  • 10.4.2 Market Forecast

11 Market Breakup by Region

• 11.1 North America
  • 11.1.1 United States
    • 11.1.1.1 Market Trends
    • 11.1.1.2 Market Forecast
  • 11.1.2 Canada
    • 11.1.2.1 Market Trends
    • 11.1.2.2 Market Forecast
• 11.2 Asia Pacific
  • 11.2.1 China
    • 11.2.1.1 Market Trends
    • 11.2.1.2 Market Forecast
  • 11.2.2 Japan
    • 11.2.2.1 Market Trends
    • 11.2.2.2 Market Forecast
  • 11.2.3 India
    • 11.2.3.1 Market Trends
    • 11.2.3.2 Market Forecast
  • 11.2.4 South Korea
    • 11.2.4.1 Market Trends
    • 11.2.4.2 Market Forecast
  • 11.2.5 Australia
    • 11.2.5.1 Market Trends
    • 11.2.5.2 Market Forecast
  • 11.2.6 Indonesia
    • 11.2.6.1 Market Trends
    • 11.2.6.2 Market Forecast
  • 11.2.7 Others
    • 11.2.7.1 Market Trends
    • 11.2.7.2 Market Forecast
• 11.3 Europe
  • 11.3.1 Germany
    • 11.3.1.1 Market Trends
    • 11.3.1.2 Market Forecast
  • 11.3.2 France
    • 11.3.2.1 Market Trends
    • 11.3.2.2 Market Forecast
  • 11.3.3 United Kingdom
    • 11.3.3.1 Market Trends
    • 11.3.3.2 Market Forecast
  • 11.3.4 Italy
    • 11.3.4.1 Market Trends
    • 11.3.4.2 Market Forecast
  • 11.3.5 Spain
    • 11.3.5.1 Market Trends
    • 11.3.5.2 Market Forecast
  • 11.3.6 Russia
    • 11.3.6.1 Market Trends
    • 11.3.6.2 Market Forecast
  • 11.3.7 Others
    • 11.3.7.1 Market Trends
    • 11.3.7.2 Market Forecast
• 11.4 Latin America
  • 11.4.1 Brazil
    • 11.4.1.1 Market Trends
    • 11.4.1.2 Market Forecast
  • 11.4.2 Mexico
    • 11.4.2.1 Market Trends
    • 11.4.2.2 Market Forecast
  • 11.4.3 Others
    • 11.4.3.1 Market Trends
    • 11.4.3.2 Market Forecast
• 11.5 Middle East and Africa
  • 11.5.1 Market Trends
  • 11.5.2 Market Breakup by Country
  • 11.5.3 Market Forecast

12 SWOT Analysis

• 12.1 Overview
• 12.2 Strengths
• 12.3 Weaknesses
• 12.4 Opportunities
• 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

• 14.1 Overview
• 14.2 Bargaining Power of Buyers
• 14.3 Bargaining Power of Suppliers
• 14.4 Degree of Competition
• 14.5 Threat of New Entrants
• 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

• 16.1 Market Structure
• 16.2 Key Players
• 16.3 Profiles of Key Players
  • 16.3.1 AbbVie Inc.
    • 16.3.1.1 Company Overview
    • 16.3.1.2 Product Portfolio
    • 16.3.1.3 Financials
    • 16.3.1.4 SWOT Analysis
  • 16.3.2 Alexion Pharmaceuticals Inc.
    • 16.3.2.1 Company Overview
    • 16.3.2.2 Product Portfolio
    • 16.3.2.3 Financials
    • 16.3.2.4 SWOT Analysis
  • 16.3.3 Amgen Inc.
    • 16.3.3.1 Company Overview
    • 16.3.3.2 Product Portfolio
    • 16.3.3.3 Financials
    • 16.3.3.4 SWOT Analysis
  • 16.3.4 Biogen Inc.
    • 16.3.4.1 Company Overview
    • 16.3.4.2 Product Portfolio
    • 16.3.4.3 Financials
    • 16.3.4.4 SWOT Analysis
  • 16.3.5 Bristol Myers Squibb Company
    • 16.3.5.1 Company Overview
    • 16.3.5.2 Product Portfolio
    • 16.3.5.3 Financials
    • 16.3.5.4 SWOT Analysis
  • 16.3.6 F. Hoffmann-La Roche AG (Roche Holding AG)
    • 16.3.6.1 Company Overview
    • 16.3.6.2 Product Portfolio
    • 16.3.6.3 SWOT Analysis
  • 16.3.7 Jazz Pharmaceuticals Plc
    • 16.3.7.1 Company Overview
    • 16.3.7.2 Product Portfolio
    • 16.3.7.3 Financials
    • 16.3.7.4 SWOT Analysis
  • 16.3.8 Johnson & Johnson
    • 16.3.8.1 Company Overview
    • 16.3.8.2 Product Portfolio
    • 16.3.8.3 Financials
    • 16.3.8.4 SWOT Analysis
  • 16.3.9 Merck & Co. Inc.
    • 16.3.9.1 Company Overview
    • 16.3.9.2 Product Portfolio
    • 16.3.9.3 Financials
    • 16.3.9.4 SWOT Analysis
  • 16.3.10 Novartis AG
    • 16.3.10.1 Company Overview
    • 16.3.10.2 Product Portfolio
    • 16.3.10.3 Financials
    • 16.3.10.4 SWOT Analysis
  • 16.3.11 Pfizer Inc.
    • 16.3.11.1 Company Overview
    • 16.3.11.2 Product Portfolio
    • 16.3.11.3 Financials
    • 16.3.11.4 SWOT Analysis
  • 16.3.12 Sanofi S.A.
    • 16.3.12.1 Company Overview
    • 16.3.12.2 Product Portfolio
    • 16.3.12.3 Financials
    • 16.3.12.4 SWOT Analysis
  • 16.3.13 Takeda Pharmaceutical Company Limited
    • 16.3.13.1 Company Overview
    • 16.3.13.2 Product Portfolio
    • 16.3.13.3 Financials
    • 16.3.13.4 SWOT Analysis
  • 16.3.14 Teva Pharmaceutical Industries Ltd
    • 16.3.14.1 Company Overview
    • 16.3.14.2 Product Portfolio
    • 16.3.14.3 Financials
    • 16.3.14.4 SWOT Analysis

List of Figures

• Figure 1: Global: Orphan Drugs Market: Major Drivers and Challenges
• Figure 2: Global: Orphan Drugs Market: Sales Value (in Billion USD), 2019-2024
• Figure 3: Global: Orphan Drugs Market: Breakup by Drug Type (in %), 2024
• Figure 4: Global: Orphan Drugs Market: Breakup by Disease Type (in %), 2024
• Figure 5: Global: Orphan Drugs Market: Breakup by Phase (in %), 2024
• Figure 6: Global: Orphan Drugs Market: Breakup by Top Selling Drugs (in %), 2024
• Figure 7: Global: Orphan Drugs Market: Breakup by Distribution Channel (in %), 2024
• Figure 8: Global: Orphan Drugs Market: Breakup by Region (in %), 2024
• Figure 9: Global: Orphan Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
• Figure 10: Global: Orphan Drugs (Biological) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 11: Global: Orphan Drugs (Biological) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 12: Global: Orphan Drugs (Non-Biological) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 13: Global: Orphan Drugs (Non-Biological) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 14: Global: Orphan Drugs (Oncology) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 15: Global: Orphan Drugs (Oncology) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 16: Global: Orphan Drugs (Hematology) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 17: Global: Orphan Drugs (Hematology) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 18: Global: Orphan Drugs (Neurology) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 19: Global: Orphan Drugs (Neurology) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 20: Global: Orphan Drugs (Cardiovascular) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 21: Global: Orphan Drugs (Cardiovascular) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 22: Global: Orphan Drugs (Other Disease Types) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 23: Global: Orphan Drugs (Other Disease Types) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 24: Global: Orphan Drugs (Phase I) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 25: Global: Orphan Drugs (Phase I) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 26: Global: Orphan Drugs (Phase II) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 27: Global: Orphan Drugs (Phase II) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 28: Global: Orphan Drugs (Phase III) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 29: Global: Orphan Drugs (Phase III) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 30: Global: Orphan Drugs (Phase IV) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 31: Global: Orphan Drugs (Phase IV) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 32: Global: Orphan Drugs (Revlimid) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 33: Global: Orphan Drugs (Revlimid) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 34: Global: Orphan Drugs (Rituxan) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 35: Global: Orphan Drugs (Rituxan) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 36: Global: Orphan Drugs (Copaxone) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 37: Global: Orphan Drugs (Copaxone) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 38: Global: Orphan Drugs (Opdivo) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 39: Global: Orphan Drugs (Opdivo) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 40: Global: Orphan Drugs (Keytruda) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 41: Global: Orphan Drugs (Keytruda) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 42: Global: Orphan Drugs (Imbruvica) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 43: Global: Orphan Drugs (Imbruvica) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 44: Global: Orphan Drugs (Avonex) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 45: Global: Orphan Drugs (Avonex) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 46: Global: Orphan Drugs (Sensipar) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 47: Global: Orphan Drugs (Sensipar) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 48: Global: Orphan Drugs (Soliris) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 49: Global: Orphan Drugs (Soliris) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 50: Global: Orphan Drugs (Other Drugs) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 51: Global: Orphan Drugs (Other Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 52: Global: Orphan Drugs (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 53: Global: Orphan Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 54: Global: Orphan Drugs (Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 55: Global: Orphan Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 56: Global: Orphan Drugs (Online Stores) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 57: Global: Orphan Drugs (Online Stores) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 58: Global: Orphan Drugs (Other Distribution Channels) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 59: Global: Orphan Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 60: North America: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 61: North America: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 62: United States: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 63: United States: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 64: Canada: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 65: Canada: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 66: Asia Pacific: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 67: Asia Pacific: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 68: China: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 69: China: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 70: Japan: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 71: Japan: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 72: India: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 73: India: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 74: South Korea: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 75: South Korea: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 76: Australia: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 77: Australia: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 78: Indonesia: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 79: Indonesia: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 80: Others: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 81: Others: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 82: Europe: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 83: Europe: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 84: Germany: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 85: Germany: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 86: France: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 87: France: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 88: United Kingdom: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 89: United Kingdom: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 90: Italy: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 91: Italy: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 92: Spain: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 93: Spain: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 94: Russia: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 95: Russia: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 96: Others: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 97: Others: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 98: Latin America: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 99: Latin America: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 100: Brazil: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 101: Brazil: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 102: Mexico: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 103: Mexico: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 104: Others: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 105: Others: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 106: Middle East and Africa: Orphan Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 107: Middle East and Africa: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 108: Global: Orphan Drugs Industry: SWOT Analysis
• Figure 109: Global: Orphan Drugs Industry: Value Chain Analysis
• Figure 110: Global: Orphan Drugs Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Orphan Drugs Market: Key Industry Highlights, 2024 and 2033
• Table 2: Global: Orphan Drugs Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
• Table 3: Global: Orphan Drugs Market Forecast: Breakup by Disease Type (in Million USD), 2025-2033
• Table 4: Global: Orphan Drugs Market Forecast: Breakup by Phase (in Million USD), 2025-2033
• Table 5: Global: Orphan Drugs Market Forecast: Breakup by Top Selling Drugs (in Million USD), 2025-2033
• Table 6: Global: Orphan Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
• Table 7: Global: Orphan Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
• Table 8: Global: Orphan Drugs Market Structure
• Table 9: Global: Orphan Drugs Market: Key Players